Abstract
Aberrant O-glycans expressed at the surface of cancer cells consist of membrane-tethered glycoproteins (T and Tn antigens) and glycolipids (Lewis a, Lewis x and Forssman antigens). All of these O-glycans have been identified as glyco-markers of interest for the diagnosis and the prognosis of cancer diseases. These epitopes are specifically detected using T/Tn-specific lectins isolated from various plants such as jacalin from Artocarpus integrifola, and fungi such as the Agaricus bisporus lectin. These lectins accommodate T/Tn antigens at the monosaccharide-binding site; residues located in the surrounding extended binding-site of the lectins often participate in the binding of more extended epitopes. Depending on the shape and size of the extended carbohydrate-binding site, their fine sugar-binding specificity towards complex O-glycans readily differs from one lectin to another, resulting in a great diversity in their sugar-recognition capacity. T/Tn-specific lectins have been extensively used for the histochemical detection of cancer cells in biopsies and for the follow up of the cancer progression and evolution. T/Tn-specific lectins also induce a caspase-dependent apoptosis in cancer cells, often associated with a more or less severe inhibition of proliferation. Moreover, they provide another potential source of molecules adapted to the building of photosensitizer-conjugates allowing a specific targeting to cancer cells, for the photodynamic treatment of tumors.
Highlights
The malignant transformation is accompanied by profound alterations in both the N- and O-glycosylation processes in healthy cells [1,2,3]
Plant and fungal lectins displaying a T/Tn-specificity have been widely used as relevant probes for the histochemical detection of aberrant O-glycan glycomarkers expressed at the surface of malignant cells
With the aid of the fast-developing glycan- and lectin-microarray technologies, our increasing knowledge on the fine carbohydrate-binding specificity of plant and fungal lectins has revealed the extreme versatility of the lectin tool to recognize discrete/subtle differences in the expression of altered glycans by cancer cells
Summary
The malignant transformation is accompanied by profound alterations in both the N- and O-glycosylation processes in healthy cells [1,2,3]. Mucin, a heavily O-GalNAc glycosylated protein, is overexpressed and subsequently secreted by cancer cells, essentially at the last stages of the malignant progression [13,14]. All of these aberrant O-glycans may serve as potential targets to improve the diagnosis and the treatment of tumors, provided the molecular probes are available for their specific recognition [15,16,17]. We present an updated review on the potential use of plant and fungal lectins as probes for both the diagnosis, the prognosis, and the treatment of cancer
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.